FibroBiologics, Inc. Common Stock

NASDAQ: FBLG · Healthcare · Biotechnology

PublicHQ Houston, DE · KentCIK 0001958777Reports USD

#1 of 1,418 Healthcare companies by revenue

EA Score

——

FH 30DQ —GM —SS 26

v0.1 · 35/100 weight · pillars only

↑ filing timeliness, balance-sheet leverage · ↓ listing tenure, return on equity

Methodology →

Revenue TTM

Rev growth YoY (TTM)

needs 8 qtrs

Net income (FY)

-$18.6M

Employees

as of 2026-08-25

Market cap

$2.8M

as of 2026-08-25

Financials — latest annual

SEC EDGAR · USD-normalized

ConceptUSDNativeFY

Net income-$18.6M-$18.6M2025

Operating income-$16.6M-$16.6M2025

Total assets$9.6M$9.6M2025

Liabilities$3.5M$3.5M2025

Equity$6.2M$6.2M2025

Revenue by segment

No segmentation disclosed for this filer. n/a

The read

What is FibroBiologics, Inc. Common Stock’s financial profile?

FibroBiologics, Inc. Common Stock earned -$18.6M in FY2025 net income.

Peers · Healthcare

Standard Dental Labs Inc.——TransCode Therapeutics, Inc.——Enzolytics Inc.——Strainsforpains, Inc.——Accustem Sciences Inc.——Avricore Health Inc.——

Neighbors

Kent →

Chesapeake Utilities Corporation$930.0M70B XFLH Capital Corporation——Metatron Inc.——Pacific Green Technologies Inc.$14.5M——Hero Technologies Inc.$0——Winning Brands Corporation——

Key facts

CEOPeter O'Heeron

SectorHealthcare

IndustryBiotechnology

HeadquartersHouston, DE

ExchangeNASDAQ: FBLG

Employees15

IPO date2024-02-01

Latest filings

8-K2026-08-24 10-Q2026-07-31 DEF 14A2026-07-31 8-K2026-07-24 8-K2026-07-09 8-K2026-06-29 8-K2026-06-23 8-K2026-05-06

Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.